Current diagnostic markers, such as cerebrospinal fluid (CSF) Aβ and tau proteins, along with neuroimaging techniques like MRI, tau-PET, β-amyloid-PET, and F-FDG-PET, facilitate early AD detection but are limited by invasiveness, cost, and accessibility4. The gene discussed is MAPT; the disease is Alzheimer disease.